Saur Dieter, Seidler Barbara, Schneider Günter, Algül Hana, Beck Roswitha, Senekowitsch-Schmidtke Reingard, Schwaiger Markus, Schmid Roland M
Department of Internal Medicine 2, Technical University of Munich, Germany.
Gastroenterology. 2005 Oct;129(4):1237-50. doi: 10.1053/j.gastro.2005.06.056.
BACKGROUND & AIMS: Expression of the Gi-protein-coupled chemokine receptor CXCR4 has recently been linked to increased proliferation, invasion, and migration of human pancreatic cancer cell lines. However, the relevance of CXCR4 for organ-specific pancreatic cancer metastasis in vivo remains unclear. Here, we have studied the role of CXCR4 in vivo using noninvasive imaging of targeted metastasis in a mouse model of pancreatic cancer.
Functional expression of the chemokine receptors CXCR4 and CCR7 was achieved by stable transfection of murine TD-2 pancreatic cancer cells and analyzed by flow cytometry, calcium flux, migration, and proliferation assays. The metastatic potential of the different stable TD-2 cell clones was assessed by tail vein metastatic assays in nude mice using in vivo bioluminescent imaging.
Native TD-2 cells display very low abundant CXCR4 and CCR7 expression and show poor metastatic potential after tail vein injection. To study the role of CXCR4 in pancreatic cancer metastasis, we selected stable TD-2 cell clones with similar CXCR4 expression levels as human pancreatic cancer cell lines derived from metastatic lesions. CXCR4, but not CCR7, expression dramatically increased the in vivo metastatic potential of TD-2 cells, resulting in liver and lung metastasis in nude mice. Systemic administration of the selective CXCR4 inhibitor AMD 3100 effectively blocked the enhanced metastatic potential of CXCR4-expressing pancreatic cancer cells.
These results indicate that CXCR4 expression mediates organ-specific metastasis of pancreatic cancer cells and provide preclinical evidence that blockade of the CXCL12/CXCR4 axis is a target for antimetastatic therapy.
Gi蛋白偶联趋化因子受体CXCR4的表达最近被认为与人类胰腺癌细胞系增殖、侵袭及迁移能力的增强有关。然而,CXCR4在胰腺癌器官特异性转移中的作用仍不明确。在此,我们通过对胰腺癌小鼠模型中的靶向转移进行无创成像,研究了CXCR4在体内的作用。
通过稳定转染鼠源TD-2胰腺癌细胞实现趋化因子受体CXCR4和CCR7的功能性表达,并通过流式细胞术、钙流、迁移及增殖分析进行检测。利用体内生物发光成像,通过裸鼠尾静脉转移实验评估不同稳定TD-2细胞克隆的转移潜能。
天然TD-2细胞CXCR4和CCR7表达水平极低,尾静脉注射后转移潜能较差。为研究CXCR4在胰腺癌转移中的作用,我们选择了与源自转移灶的人类胰腺癌细胞系CXCR4表达水平相似的稳定TD-2细胞克隆。CXCR4而非CCR7的表达显著增强了TD-2细胞的体内转移潜能,导致裸鼠出现肝转移和肺转移。全身给予选择性CXCR4抑制剂AMD 3100可有效阻断CXCR4表达的胰腺癌细胞增强的转移潜能。
这些结果表明,CXCR4表达介导胰腺癌细胞的器官特异性转移,并提供了临床前证据,表明阻断CXCL12/CXCR4轴是抗转移治疗的靶点。